News | August 10, 2024
Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
The state-of-the-art facility is equipped with best-in-class equipment and control systems
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Ayurveda OPD will be established in 10 ECHS Polyclinic/Dispensaries in various regions of India to cover all ECHS members on a voluntary basis
Subscribe To Our Newsletter & Stay Updated
